Systemic mirnas as potential biomarkers for malignancy

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2215-2222

  Healy, N A ^a,b   Heneghan, H M ^a   Miller, N ^a   Osborne, C K ^b   Schiff, R ^b   Kerin, M J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

circulating miRNAs; malignancy; systemic miRNAs

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 106A; MICRORNA 10B; MICRORNA 141; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 181A; MICRORNA 195; MICRORNA 199A; MICRORNA 200B; MICRORNA 21; MICRORNA 210; MICRORNA 30C 1 3P; MICRORNA 335; MICRORNA 342 3P; MICRORNA 34A; MICRORNA 375; MICRORNA 450B 5P; MICRORNA 516A 3P; MICRORNA 9; MICRORNA 92; MICRORNA LET 7A; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN EXPRESSION; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; COLORECTAL CANCER; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA ANALYSIS; RNA STABILITY; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

HUMANS; MICRORNAS; NEOPLASMS; NUCLEIC ACIDS; RNA STABILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84867081983     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27642     Document Type: Review

References (61)

1. Duffy MJ,. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007; 18: 175-84.
2. Lawrie CH, Gal S, Dunlop HM,. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5.
3. Wang GK, Zhu JQ, Zhang JT, etal. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-66.
4. Wang K, Zhang S, Marzolf B, etal. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-7.
5. Duffy MJ,. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001; 47: 624-30.
6. Loeb S, Catalona WJ,. Prostate-specific antigen in clinical practice. Cancer Lett 2007; 249: 30-9.
7. Board RE, Bruijns CT, Pronk AE, etal. Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer 2006; 16 (Suppl 1): 18-24.
8. Duffy MJ,. Serum tumor markers in breast cancer: are they of clinical value?. Clin Chem 2006; 52: 345-51.
9. Ren FY, Piao XX, In AL,. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 4656-9.
10. Fernandes LC, Kim SB, Saad SS, etal. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol 2006; 12: 3891-4.
11. Schroder FH, Hugosson J, Roobol MJ, etal. Screening and prostate cancer mortality in a randomised European Study. N Engl J Med 2009; 360: 1320-8.
12. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004). Cell 2007; 131: 11-29.
13. Croce CM,. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
14. Calin GA, Dumitru CD, Shimizu M, etal. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
15. Iorio MV, Ferracin M, Liu CG, etal. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
16. Lowery AJ, Miller N, Devaney A, etal. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11: R27.
17. Lu J, Getz G, Miska EA,. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
18. Iorio MV, Visone R, Di Leva G, etal. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-707.
19. Takamizawa J, Konishi H, Yanagisawa K, etal. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-6.
20. Mandel P, Metais P,. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948; 142: 241-3.
21. Tsang JC, Lo YM,. Circulating nucleic acids in plasma/serum. Pathology 2007; 39: 197-207.
22. Leon SA, Shapiro B, Sklaroff DM, etal. Free DNA in serum of cancer-patients and effect of therapy. Cancer Res 1977; 37: 646-50.
23. Silva J, Silva JM, Garcia V, etal. RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Genes Chromosomes Cancer 2002; 35: 375-6.
24. Chen X, Ba Y, Ma LJ, etal. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
25. Skog J, Wurdinger T, van Rijn S, etal. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-6.
26. Valadi H, Ekstrom K, Bossios A, etal. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
27. Hu Z, Chen X, Zhao Y, etal. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28: 1721-6.
28. Ratajczak J, Miekus K, Kucia M, etal. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006; 20: 847-56.
29. Hunter MP, Ismail N, Zhang X, etal. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694.
30. Taylor DD, Gercel-Taylor C,. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
31. Rabinowits G, Gercel-Taylor C, Day JM, etal. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-6.
32. Tsujiura M, Ichikawa D, Komatsu S, etal. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-9.
33. Pigati L, Yaddanapudi SC, Iyengar R, etal. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5: e13515.
34. Mitchell PS, Parkin RK, Kroh EM,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
35. Kroh EM, Parkin RK, Mitchell PS, etal. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298-301.
36. Chim SSC, Shing TKF, Hung ECW, etal. Detection and characterization of placental MicroRNAs in maternal plasma. Clin Chem 2008; 54: 482-90.
37. Turchinovich A, Weiz L, Langheinz A, etal. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-33.
38. Heneghan HM, Miller N, Lowery AJ, etal. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
39. Roth C, Rack B, Muller V, etal. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90.
40. Ng EK, Chong WW, Jin H, etal. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
41. Huang Z, Huang D, Ni S, etal. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118-26.
42. Qu KZ, Zhang K, Li H, etal. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011; 45: 355-60.
43. Hausler SF, Keller A, Chandran PA, etal. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 2010; 103: 693-700.
44. Resnick KE, Alder H, Hagan JP, etal. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112: 55-9.
45. Li A, Omura N, Hong SM, etal. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010; 70: 5226-37.
46. Brase JC, Johannes M, Schlomm T, etal. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011; 128: 608-16.
47. Ohyashiki K, Umezu T, Yoshizawa S, etal. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One 2011; 6: e16408.
48. Heneghan HM, Miller N, Kelly R, etal. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010; 15: 673-82.
49. Zhao H, Shen J, Medico L, etal. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010; 5: e13735.
50. Wang F, Zheng Z, Guo J, etal. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 2010; 119: 586-93.
51. Schaefer A, Jung M, Mollenkopf HJ, etal. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-76.
52. Collins JF, Lieberman DA, Durbin TE, etal. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142: 81-5.
53. Zhou H, Guo JM, Lou YR, etal. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med 2010; 88: 709-17.
54. Xu J, Wu C, Che X, etal. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-42.
55. Tsai WC, Hsu PW, Lai TC, etal. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-82.
56. Wong QW, Lung RW, Law PT, etal. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008; 135: 257-69.
57. Chang J, Nicolas E, Marks D, etal. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-13.
58. Foss KM, Sima C, Ugolini D, etal. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011; 6: 482-8.
59. Chen CF, Ridzon DA, Broomer AJ, etal. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
60. Schmittgen TD, Lee EJ, Jiang J, etal. Real-time PCR quantification of precursor and mature microRNA. Methods 2008; 44: 31-8.
61. Peltier HJ, Latham GJ,. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008; 14: 844-52.